Company / R&D Expense
TScan Therapeutics, Inc. R&D Expense History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$107.3M
FY2025
5-year range
$20.6M / $107.3M
FY2021-FY2025
Trend
+21.8%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
R&D Expense has increased for 4 consecutive years, from $21M in FY2021 to $107M in FY2025.
Based on SEC 10-K filings.
$107M in FY2025 with a 3-year CAGR of +33.7%.
Improved from $60M to $107M over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +33.7%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- TScan Therapeutics, Inc.'s r&d expense has grown for 4 consecutive years.
- 3-year CAGR of +33.7%, indicating consistent growth.
- In FY2025, r&d expense increased 21.8% year-over-year.
- Lowest r&d expense in the period was in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -9.69 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $107.3M | +21.8% |
| FY2024 | $88.2M | +47.4% |
| FY2023 | $59.8M | +33.1% |
| FY2022 | $45.0M | +118.5% |
| FY2021 | $20.6M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026